| Bioactivity | (Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2]. |
| Name | (Rac)-Vazegepant-13C,d3 |
| Formula | C3513CH43D3N8O3 |
| Molar Mass | 642.81 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [2]. Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63(6):2915-2929. |
(Rac)-Vazegepant-13C,d3
CAS: F: C3513CH43D3N8O3 W: 642.81
(Rac)-Vazegepant-13C,d3 is the C13 and deuterium labeled (Rac)-Vazegepant. Vazegepant (HY-134992) is the first intranasa
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.